| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/08/2022 | 258.74% | JonesTrading | → $8 | Initiates Coverage On | → Buy |
| 03/24/2022 | 79.37% | Maxim Group | → $4 | Initiates Coverage On | → Buy |
| 11/19/2021 | 348.43% | EF Hutton | → $10 | Initiates Coverage On | → Buy |
HCW Biologics Questions & Answers
The latest price target for HCW Biologics (NASDAQ: HCWB) was reported by JonesTrading on November 8, 2022. The analyst firm set a price target for $8.00 expecting HCWB to rise to within 12 months (a possible 258.74% upside). 3 analyst firms have reported ratings in the last year.
The latest analyst rating for HCW Biologics (NASDAQ: HCWB) was provided by JonesTrading, and HCW Biologics initiated their buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of HCW Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for HCW Biologics was filed on November 8, 2022 so you should expect the next rating to be made available sometime around November 8, 2023.
While ratings are subjective and will change, the latest HCW Biologics (HCWB) rating was a initiated with a price target of $0.00 to $8.00. The current price HCW Biologics (HCWB) is trading at is $2.23, which is within the analyst's predicted range.